The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
PI3K and cancer: lessons, challenges and opportunities
Open accessAbstract
The central role of phosphoinositide 3-kinase (PI3K) activation in tumour cell biology has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer. However, emerging clinical data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses. One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukaemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy. Here, we review key challenges and opportunities for the clinical development of inhibitors targeting the PI3K–AKT–mTOR pathway. Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–228 of 228
PI3K in cancer–stroma interactions: bad in seed and ugly in soil
Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A., & Martini, M. (2013) · Oncogene · doi:10.1038/onc.2013.265 · Cited by 77
Pancreatic tumours escape from translational control through 4E-BP1 loss
Martineau, Y., Azar, R., Müller, D., Lasfargues, C., Khawand, S. E., Anesia, R., Pelletier, J., Bousquet, C., & Pyronnet, S. (2013) · Oncogene · doi:10.1038/onc.2013.100 · Cited by 75
Berenjeno, I. M., Guillermet‐Guibert, J., Pearce, W. P., Gray, A., Fleming, S., & Vanhaesebroeck, B. (2011) · Biochemical Journal · doi:10.1042/bj20111741 · Cited by 73
Combination Checkpoint Blockade — Taking Melanoma Immunotherapy to the Next Level
Riley, J. L. (2013) · New England Journal of Medicine · doi:10.1056/nejme1305484 · Cited by 72
Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis
Soler, A., Serra, H., Pearce, W. P., Angulo‐Urarte, A., Guillermet‐Guibert, J., Friedman, L. S., Viñals, F., Gerhardt, H., Casanovas, O., Graupera, M., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121571 · Cited by 72
PI3Ks in Lymphocyte Signaling and Development
Okkenhaug, K., & Fruman, D. A. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_45 · Cited by 70
Self-citationFloris, G., Woźniak, A., Sciot, R., Li, H., Friedman, L. S., Looy, T. V., Wellens, J., Vermaelen, P., Deroose, C. M., Fletcher, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2853 · Cited by 70
Yang, J., Wang, J., Chen, K., Guo, G., Xi, R., Rothman, P. B., Whitten, D. A., Zhang, L., Huang, S., & Chen, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4277 · Cited by 69
Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function*
So, L., Yea, S. S., Oak, J. S., Lu, M., Manmadhan, A., Ke, Q. H., Janes, M. R., Kessler, L. V., Kucharski, J. M., Li, L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.379446 · Cited by 68
Self-citationBlanco‐Aparicio, C., Collazo, A., Oyarzábal, J., Martínez-Leal, J. F., Albarán, M. I., Ramos-Lima, F., Pequeño, B., Ajenjo, N., Becerra, M., Alfonso, P., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.09.016 · Cited by 67
Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape
Burger, J. A. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283589950 · Cited by 66
Tikoo, A., Roh, V., Montgomery, K. G., Ivetac, I., Waring, P., Pelzer, R., Hare, L., Shackleton, M. J., Humbert, P. O., & Phillips, W. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036924 · Cited by 65
Song, J. H., & Kraft, A. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-3240 · Cited by 64
Rexer, B. N., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0687 · Cited by 55
Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
Dbouk, H. A., Khalil, B. D., Wu, H., Shymanets, A., Nürnberg, B., & Backer, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063833 · Cited by 54
Berndt, A., Miller, S., Williams, O., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio0310-244b · Cited by 49
Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells
Liu, Y., Sun, S., Owonikoko, T. K., Sica, G., Curran, W. J., Khuri, F. R., & Deng, X. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0578 · Cited by 48
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
Macias‐Perez, I., & Flinn, I. W. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0142-1 · Cited by 47
PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target
Zhao, J. J., & Roberts, T. (2006) · Science's STKE · doi:10.1126/stke.3652006pe52 · Cited by 47
Targeting TOR dependence in cancer
Janes, M. R., & Fruman, D. A. (2010) · Oncotarget · doi:10.18632/oncotarget.110 · Cited by 46
Self-citationInhibitors of Translation Initiation as Cancer Therapeutics
Lindqvist, L., & Pelletier, J. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.122 · Cited by 43
Targeting AMPK in the treatment of malignancies
Vakana, E., Altman, J. K., & Platanias, L. C. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23369 · Cited by 37
Boyle, D. L., Kim, H., Topolewski, K., Bartók, B., & Firestein, G. S. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.205955 · Cited by 37
An overview of the mTOR pathway as a target in cancer therapy
Gentzler, R. D., Altman, J. K., & Platanias, L. C. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.677439 · Cited by 36
Guo, D., Teng, Q., & Ji, C. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.564696 · Cited by 34
Young, C. D., Pfefferle, A. D., Owens, P., Kuba, M. G., Rexer, B. N., Balko, J. M., Sanchez, V. M., Cheng, H.-L. M., Perou, C. M., Zhao, J. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4579 · Cited by 29
mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
Alain, T., Sonenberg, N., & Topisirović, I. (2012) · Oncotarget · doi:10.18632/oncotarget.799 · Cited by 19
A Lipid Kinase Cousin Cooperates to Promote Cancer
Beagle, B. R., & Fruman, D. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.020 · Cited by 16
Self-citation
Cited by
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Metadata
- Authors
- Fruman, D. A., & Rommel, C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-01-31
- Volume
- 13
- Issue
- 2
- Pages
- 140-156
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2054917860
- Cited by
- 1,709
- References
- 228
- FWCI
- 13.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.